Our Focus

Fennec Supported Clinical Trials

Phase 3 Pivotal Data Publications:

• New England Journal of Medicine: Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
• Lancet Oncology: Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial

Compassionate Use Program (Turkey):

• Patient Population: Newly Diagnosed Hepatoblastoma
• Start date: Oct 21, 2019
• Duration: 3 years accrual + 1 year follow-up

STS J-01: Phase 2/3: Hiroshima University

• Patient Population: Pediatric and AYA patients (<39 years old)
• Tumor Type: Non-metastatic solid tumors
• Status: Complete
• JRCT number: jRCT2061220018

Mount Sinai Hospital & UCLA: Feasibility of Sodium Thiosulfate (STS) Administration for Ototoxicity Prevention During Cisplatin-Based Treatment

• Patient Population: AYA and Adults (>18 years old)
• Tumor Type: Head and Neck Cancer
• Status: Complete
• Poster Presentation: 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS)

City of Hope: Testing the Addition of PEDMARK® to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage

• Patient Population: AYA & Adult men (>18 years old)
• Tumor Type: Stage II-III Metastatic Testicular Germ Cell Tumors
• Status: Active, Recruiting
• NCT number: NCT07218913

Tampa General Hospital Cancer Institute: Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity

• Patient Population: AYA and Adult (>18 years old)
• Tumor Type: Non-Metastatic Solid Tumors
• Status: Active, Recruiting

University of Arizona Cancer Center: Phase I/II Open-Label Trial of Intravenous Sodium Thiosulfate (PEDMARK®) as Otoprotectant

• Patient Population: AYA and Adult (>18 years old)
• Tumor Type: Non-Metastatic Solid Tumors
• Status: Active, Recruiting
• NCT number: NCT07407582